Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$291.99 USD
+37.11 (14.56%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $291.86 -0.13 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MDGL 291.99 +37.11(14.56%)
Will MDGL be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDGL
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
2 Top Biotech Buyout Candidates
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Other News for MDGL
Wolfe Research starts Akero at outperform, cites MASH drug prospects
10 Health Care Stocks With Whale Alerts In Today's Session
Wolfe starts Madrigal at outperform, cites Rezdiffra launch
Tracking Baker Brothers Portfolio - Q1 2024 Update
TD Cowen Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)